Emergent BioSolutions (EBS) Income from Continuing Operations (2011 - 2026)

Emergent BioSolutions' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 6800000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 90.0% year-over-year to 6800000.0; the TTM figure through Mar 2026 stood at 8600000.0 (up 93.47% YoY), while the FY2025 annual figure was 52600000.0, up 127.6% from the prior year.
• Income from Continuing Operations was 6800000.0 for Q1 2026 at Emergent BioSolutions, up from 54600000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 114800000.0 in Q3 2024 to a low of 283100000.0 in Q2 2024.
• Historically, Income from Continuing Operations has averaged 65052941.18 across 5 years, with a median of 49500000.0 in 2023.
• The sharpest annual moves came in 2023 and 2025: Income from Continuing Operations slumped 4932.43% in 2023, then jumped 655.56% in 2025.
• A 5-year view of Income from Continuing Operations shows it stood at 67000000.0 in 2022, then gained by 26.12% to 49500000.0 in 2023, then jumped by 36.77% to 31300000.0 in 2024, then tumbled by 74.44% to 54600000.0 in 2025, then soared by 112.45% to 6800000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 6800000.0 (Q1 2026), 54600000.0 (Q4 2025), and 51200000.0 (Q3 2025), per Business Quant data.